Premium
EFFECTS OF ADRENALINE, ISOPRENALINE AND FORSKOLIN ON PREGNANT HUMAN MYOMETRIAL PREPARATIONS
Author(s) -
Story Margot E.,
Hall Solveiga,
Ziccone Sebastian P.,
Paull John D.
Publication year - 1988
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1988.tb01130.x
Subject(s) - isoprenaline , forskolin , endocrinology , medicine , inhibitory postsynaptic potential , cyclase , chemistry , myometrium , adenylate kinase , antagonist , agonist , terbutaline , receptor , uterus , biology , stimulation , asthma
SUMMARY 1. The effects of adrenaline, isoprenaline and forskolin upon the evoked contractions of field‐stimulated preparations of human, pregnant, isolated myometrium have been examined. Specimens were obtained at lower segment Caesarean section from patients at 31 ( n = 1) and 36–40 ( n = 10) weeks of gestation. 2. Adrenaline enhanced the electrically evoked contractions of all preparations studied, indicating that its predominant action on these pregnant myometrial tissues was at α‐and not β‐adrenoceptors. 3. Isoprenaline in concentrations at and below 10 μmol/1 produced inhibitory effects in eight of 11 experiments. In the remaining three experiments, tissues were not responsive to the inhibitory effects of isoprenaline. 4. In all preparations exposed to higher concentrations of isoprenaline (30 or 100 μmol/1), its effects were excitatory. 5. Forskolin produced inhibitory effects on preparations from all uteri, including those from which tissues unresponsive to isoprenaline had been obtained. 6. It is suggested that forskolin in the concentrations which were effective in this study produced its inhibitory effects largely through activation of adenylate cyclase. This implies that the lack of an inhibitory response of some preparations to isoprenaline was not due to reduced activity of the adenylate cyclase system, but that the failure of isoprenaline to produce an inhibitory effect could be due to diminished numbers of β‐adrenoceptors and/or increased numbers of α‐adrenoceptors, or to a defect in the coupling of the receptors to the adenylate cyclase system. Alternatively, the presence of an endogenous antagonist of the effects of isoprenaline (for example, an eicosanoid), could mask its inhibitory effects. 7. The absence of an inhibitory effect of isoprenaline on some specimens of human gravid myometrium could have clinical implications, in view of the widespread use of β 2 ‐adrenoceptor agonists as uterine relaxants.